ADAPTIVE BIOTECHNOLOGIES (ADPT) Stock Fundamental Analysis

NASDAQ:ADPT • US00650F1093

16.05 USD
+0.18 (+1.13%)
At close: Feb 19, 2026
16.2 USD
+0.15 (+0.93%)
After Hours: 2/19/2026, 4:30:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall ADPT gets a fundamental rating of 2 out of 10. We evaluated ADPT against 58 industry peers in the Life Sciences Tools & Services industry. ADPT has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, ADPT is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ADPT has reported negative net income.
  • ADPT had a negative operating cash flow in the past year.
  • ADPT had negative earnings in each of the past 5 years.
  • In the past 5 years ADPT always reported negative operating cash flow.
ADPT Yearly Net Income VS EBIT VS OCF VS FCFADPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M -200M

1.2 Ratios

  • The Return On Assets of ADPT (-16.29%) is worse than 60.34% of its industry peers.
  • The Return On Equity of ADPT (-39.09%) is worse than 65.52% of its industry peers.
Industry RankSector Rank
ROA -16.29%
ROE -39.09%
ROIC N/A
ROA(3y)-25.08%
ROA(5y)-24.21%
ROE(3y)-59.64%
ROE(5y)-51.27%
ROIC(3y)N/A
ROIC(5y)N/A
ADPT Yearly ROA, ROE, ROICADPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

  • ADPT has a Gross Margin of 71.84%. This is amongst the best in the industry. ADPT outperforms 94.83% of its industry peers.
  • In the last couple of years the Gross Margin of ADPT has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for ADPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 71.84%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.59%
GM growth 5Y-0.76%
ADPT Yearly Profit, Operating, Gross MarginsADPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • ADPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ADPT has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ADPT has more shares outstanding
  • Compared to 1 year ago, ADPT has a worse debt to assets ratio.
ADPT Yearly Shares OutstandingADPT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
ADPT Yearly Total Debt VS Total AssetsADPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • Based on the Altman-Z score of 1.74, we must say that ADPT is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of ADPT (1.74) is better than 60.34% of its industry peers.
  • ADPT has a Debt/Equity ratio of 0.63. This is a neutral value indicating ADPT is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.63, ADPT is doing worse than 68.97% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF N/A
Altman-Z 1.74
ROIC/WACCN/A
WACC10.82%
ADPT Yearly LT Debt VS Equity VS FCFADPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • ADPT has a Current Ratio of 3.38. This indicates that ADPT is financially healthy and has no problem in meeting its short term obligations.
  • ADPT has a Current ratio (3.38) which is in line with its industry peers.
  • A Quick Ratio of 3.26 indicates that ADPT has no problem at all paying its short term obligations.
  • The Quick ratio of ADPT (3.26) is better than 60.34% of its industry peers.
Industry RankSector Rank
Current Ratio 3.38
Quick Ratio 3.26
ADPT Yearly Current Assets VS Current LiabilitesADPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • ADPT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 63.30%, which is quite impressive.
  • ADPT shows a strong growth in Revenue. In the last year, the Revenue has grown by 54.77%.
  • Measured over the past years, ADPT shows a very strong growth in Revenue. The Revenue has been growing by 23.00% on average per year.
EPS 1Y (TTM)63.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.87%
Revenue 1Y (TTM)54.77%
Revenue growth 3Y14.34%
Revenue growth 5Y23%
Sales Q2Q%51.04%

3.2 Future

  • The Earnings Per Share is expected to grow by 14.58% on average over the next years. This is quite good.
  • Based on estimates for the next years, ADPT will show a quite strong growth in Revenue. The Revenue will grow by 19.37% on average per year.
EPS Next Y-51.09%
EPS Next 2Y1.9%
EPS Next 3Y17.8%
EPS Next 5Y14.58%
Revenue Next Year0.53%
Revenue Next 2Y11.22%
Revenue Next 3Y13.81%
Revenue Next 5Y19.37%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
ADPT Yearly Revenue VS EstimatesADPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
ADPT Yearly EPS VS EstimatesADPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • ADPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADPT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ADPT Price Earnings VS Forward Price EarningsADPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ADPT Per share dataADPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ADPT's earnings are expected to grow with 17.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.9%
EPS Next 3Y17.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ADPT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ADAPTIVE BIOTECHNOLOGIES

NASDAQ:ADPT (2/19/2026, 4:30:00 PM)

After market: 16.2 +0.15 (+0.93%)

16.05

+0.18 (+1.13%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-05
Earnings (Next)04-29
Inst Owners96.97%
Inst Owner Change2.85%
Ins Owners2.33%
Ins Owner Change-7.32%
Market Cap2.47B
Revenue(TTM)276.98M
Net Income(TTM)-79.92M
Analysts84.29
Price Target20.4 (27.1%)
Short Float %6%
Short Ratio3.85
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)85.21%
Min EPS beat(2)30.19%
Max EPS beat(2)140.22%
EPS beat(4)4
Avg EPS beat(4)53.85%
Min EPS beat(4)12%
Max EPS beat(4)140.22%
EPS beat(8)8
Avg EPS beat(8)33.22%
EPS beat(12)10
Avg EPS beat(12)23.99%
EPS beat(16)14
Avg EPS beat(16)20.79%
Revenue beat(2)2
Avg Revenue beat(2)29.69%
Min Revenue beat(2)16.85%
Max Revenue beat(2)42.52%
Revenue beat(4)4
Avg Revenue beat(4)20.23%
Min Revenue beat(4)1.07%
Max Revenue beat(4)42.52%
Revenue beat(8)7
Avg Revenue beat(8)12.77%
Revenue beat(12)9
Avg Revenue beat(12)7.89%
Revenue beat(16)12
Avg Revenue beat(16)5.97%
PT rev (1m)0.72%
PT rev (3m)21.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.68%
EPS NY rev (1m)-3.04%
EPS NY rev (3m)3.27%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 9.77
P/FCF N/A
P/OCF N/A
P/B 12.07
P/tB 29.63
EV/EBITDA N/A
EPS(TTM)-0.4
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS1.64
BVpS1.33
TBVpS0.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -16.29%
ROE -39.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 71.84%
FCFM N/A
ROA(3y)-25.08%
ROA(5y)-24.21%
ROE(3y)-59.64%
ROE(5y)-51.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.59%
GM growth 5Y-0.76%
F-Score5
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.3%
Cap/Sales 0.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.38
Quick Ratio 3.26
Altman-Z 1.74
F-Score5
WACC10.82%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.87%
EPS Next Y-51.09%
EPS Next 2Y1.9%
EPS Next 3Y17.8%
EPS Next 5Y14.58%
Revenue 1Y (TTM)54.77%
Revenue growth 3Y14.34%
Revenue growth 5Y23%
Sales Q2Q%51.04%
Revenue Next Year0.53%
Revenue Next 2Y11.22%
Revenue Next 3Y13.81%
Revenue Next 5Y19.37%
EBIT growth 1Y53.14%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year50.83%
EBIT Next 3Y47.1%
EBIT Next 5Y24.27%
FCF growth 1Y45.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.38%
OCF growth 3YN/A
OCF growth 5YN/A

ADAPTIVE BIOTECHNOLOGIES / ADPT FAQ

Can you provide the ChartMill fundamental rating for ADAPTIVE BIOTECHNOLOGIES?

ChartMill assigns a fundamental rating of 2 / 10 to ADPT.


What is the valuation status for ADPT stock?

ChartMill assigns a valuation rating of 0 / 10 to ADAPTIVE BIOTECHNOLOGIES (ADPT). This can be considered as Overvalued.


Can you provide the profitability details for ADAPTIVE BIOTECHNOLOGIES?

ADAPTIVE BIOTECHNOLOGIES (ADPT) has a profitability rating of 1 / 10.


How financially healthy is ADAPTIVE BIOTECHNOLOGIES?

The financial health rating of ADAPTIVE BIOTECHNOLOGIES (ADPT) is 3 / 10.